IL-DISCOVER-FINANCIAL
7.6.2019 16:12:07 CEST | Business Wire | Press release
Borica AD, owner of Bulgaria’s national payment scheme Bcard and Discover Financial Services, a leading direct bank and payments services company announced that they have signed a strategic agreement that will allow acceptance of Bcard’s Global Cards outside of Bulgaria on the Discover Global Network.
To help provide safer international transactions, Bcard and Discover will collaborate on the integration of Discover’s EMV® contact, contactless and mobile solutions, D-PAS for international usage. Bcard will also provide their member banks with a solution to support the acceptance of Bcard’s Global Cards outside of Bulgaria on the Discover Global Network.
“Discover has become a nimble and flexible partner to organizations around the world by providing them the tools and resources to grow and increase acceptance,” said Joe Hurley, senior vice president and head of global business development at Discover. “This agreement with Bcard complements Discover’s strategy of creating worldwide alliances that provide consumers with more choice when it comes to how and where they pay.”
“The investment in innovation and the development of solutions as extending acceptance outside the territory of Bulgaria for our customers has always been among Bcard’s priorities,” said Mrs. Stoilka Arsova, director of Bulgarian national scheme Bcard. “Bulgaria has accumulated knowledge, experience and technology and achieved world-class standards in terms of financial technology and security and this strategic alliance with Discover reinforces Bcard's continuous efforts to diversify its card-payment services for our banks and promote Bulgaria's card-payment market development. Based on this strategic alliance, Bcard will provide their member banks with an effective competitive domestic platform, range of products and the opportunity to use innovative payment products.”
Discover Global Network has more than 44 million merchant acceptance locations and 2 million ATM and cash access locations across more than 190 countries and territories. Discover Global Network includes Discover, Diners Club International, PULSE and affiliated networks. It also includes network relationships with partners around the globe in Brazil, China, India, Japan, the Middle East, Nigeria, Puerto Rico, Serbia, South Korea, Vietnam, Taiwan, Mexico and throughout Europe.
About Bcard
Bcard National Card Scheme of Borica AD has been in operation since 2016 and functions separately and independently from the card payment processor of Borica.
All payment service providers in Bulgaria are members of the Bcard scheme. Bcard, as a Bulgarian national payment card, is accepted at all possible locations (ATM/POS) in Bulgaria. The main mission of the scheme is migration of cash and paper to digital channels through development of new electronic services in the public and private sectors in Bulgaria. Positioning the wide range of scheme products through new local business and price models is expected to have a positive impact on the economy of the country and to change radically the payment methods in Bulgaria.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005310/en/
Contact:
Media Contacts: Elena Tosheva Head of Marketing and Communications Bcard M: + 359 884 292 192 E: ETosheva@borica.bg
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
